HER2CLIMB-02: Randomized, Double-Blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-Positive Metastatic Breast Cancer

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2024年 / 22卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：16
相关论文
共 50 条
  • [21] Tucatinib and trastuzumab for previously treated HER2-positive metastatic biliary tract cancer (SGNTUC-019): A phase 2 basket study
    Nakamura, Yoshiaki
    Mizuno, Nobumasa
    Sunakawa, Yu
    Hamilton, Erika P.
    Hayashi, Hidetoshi
    Kim, Seung Tae
    Lee, Keun-Wook
    Monk, Bradley J.
    Nguyen, Danny
    Okines, Alicia Frances Clare
    O'Malley, David M.
    Pohlmann, Paula R.
    Reck, Martin
    Yu, Evan Y.
    Groisberg, Roman
    Ramos, Jorge
    Tan, Qianwen
    Stinchcombe, Tom
    Bekaii-Saab, Tanios S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [22] Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2-positive metastatic breast cancer
    Iwata, Hiroji
    Xu, Binghe
    Kim, Sung-Bae
    Chung, Wei-Pang
    Park, Yeon Hee
    Kim, Min Hwan
    Tseng, Ling-Ming
    Chung, Chi-Feng
    Huang, Chiun-Sheng
    Kim, Jee Hyun
    Chiu, Joanne Wing Yan
    Yamashita, Toshinari
    Li, Wei
    Egorov, Anton
    Nishijima, Soichiro
    Nakatani, Shunsuke
    Nishiyama, Yuji
    Sugihara, Masahiro
    Cortes, Javier
    Im, Seock-Ah
    CANCER SCIENCE, 2024, 115 (09) : 3079 - 3088
  • [23] Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
    von Minckwitz, G.
    Huang, C. -S.
    Mano, M. S.
    Loibl, S.
    Mamounas, E. P.
    Untch, M.
    Wolmark, N.
    Rastogi, P.
    Schneeweiss, A.
    Redondo, A.
    Fischer, H. H.
    Jacot, W.
    Conlin, A. K.
    Arce-Salinas, C.
    Wapnir, I. L.
    Jackisch, C.
    DiGiovanna, M. P.
    Fasching, P. A.
    Crown, J. P.
    Wuelfing, P.
    Shao, Z.
    Caremoli, E. Rota
    Wu, H.
    Lam, L. H.
    Tesarowski, D.
    Smitt, M.
    Douthwaite, H.
    Singel, S. M.
    Geyer, C. E., Jr.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (07): : 617 - 628
  • [24] Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer
    Geyer Jr, Charles E.
    Untch, Michael
    Huang, Chiun-Sheng
    Mano, Max S.
    Mamounas, Eleftherios P.
    Wolmark, Norman
    Rastogi, Priya
    Schneeweiss, Andreas
    Redondo, Andres
    Fischer, Hans H.
    D'Hondt, Veronique
    Conlin, Alison K.
    Guarneri, Valentina
    Wapnir, Irene L.
    Jackisch, Christian
    Arce-Salinas, Claudia
    Fasching, Peter A.
    Digiovanna, Michael P.
    Crown, John P.
    Wuelfing, Pia
    Shao, Zhimin
    Caremoli, Elena Rota
    Bonnefoi, Herve R.
    Hennessy, Bryan T.
    Stamatovic, Ljiljana
    Castro-Salguero, Hugo
    Brufsky, Adam M.
    Knott, Adam
    Siddiqui, Asna
    Lambertini, Chiara
    Boulet, Thomas
    Nyawira, Beatrice
    Restuccia, Eleonora
    Loibl, Sibylle
    KATHERINE Study Grp
    NEW ENGLAND JOURNAL OF MEDICINE, 2025,
  • [25] Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer
    Oostra, Drew R.
    Macrae, Erin R.
    BREAST CANCER-TARGETS AND THERAPY, 2014, 6 : 103 - 113
  • [26] Exposure–response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane
    Chunze Li
    Bei Wang
    Shang-Chiung Chen
    Russell Wada
    Dan Lu
    Xin Wang
    Daniel Polhamus
    Jonathan French
    Shweta Vadhavkar
    Alexander Strasak
    Melanie Smitt
    Amita Joshi
    Meghna Samant
    Angelica Quartino
    Jin Jin
    Sandhya Girish
    Cancer Chemotherapy and Pharmacology, 2017, 80 : 1079 - 1090
  • [27] Trastuzumab emtansine (Kadcyla®) approval in HER2-positive metastatic breast cancers
    Guerin, Mathilde
    Sabatier, Renaud
    Goncalves, Anthony
    BULLETIN DU CANCER, 2015, 102 (04) : 390 - 397
  • [28] HER2CLIMB-02: Tucatinib or placebo with T-DM1 for unresectable locally-advanced or metastatic HER2+breast cancer
    Hurvitz, S. A.
    Harbeck, N.
    Vahdat, L.
    Wolff, A. C.
    Tolaney, S. M.
    Loi, S.
    Masuda, N.
    O'Shaughnessy, J.
    Xie, D.
    Walker, L. N.
    Rustia, E.
    Borges, V.
    ANNALS OF ONCOLOGY, 2021, 32 : S75 - S75
  • [29] Tucatinib vs placebo added to trastuzumab and capecitabine in previously treated HER2+metastatic breast cancer with and without brain metastases (HER2CLIMB)
    Curigliano, G.
    Murthy, R.
    Loi, S.
    Okines, A.
    Paplomata, E.
    Hamilton, E.
    Hurvitz, S. A.
    Cameron, D.
    Borges, V.
    Bedard, P.
    Oliveira, M.
    Jakobsen, E. H.
    Bachelot, T.
    Shachar, S. S.
    Mueller, V.
    Carey, L. A.
    Loibl, S.
    Feng, W.
    Walker, L. N.
    Winer, E.
    ANNALS OF ONCOLOGY, 2020, 31 : S62 - S63
  • [30] Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+metastatic breast cancer with brain metastases (HER2CLIMB).
    Lin, Nancy U.
    Murthy, Rashmi Krishna
    Anders, Carey K.
    Borges, Virginia F.
    Hurvitz, Sara A.
    Loi, Sherene
    Abramson, Vandana G.
    Bedard, Philippe L.
    Oliveira, Mafalda
    Zelnak, Amelia Bruce
    DiGiovanna, Michael
    Bachelot, Thomas
    Chien, Amy Jo
    O'Regan, Ruth
    Wardley, Andrew M.
    Mueller, Volkmar
    Carey, Lisa A.
    McGoldrick, Suzanne M.
    An, Grace
    Winer, Eric P.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345